AHS19

Lynch syndrome (LS) is an autosomal dominant disorder which predisposes patients to specific types of cancer and is caused by mutations of four mismatch repair (MMR) genes. LS mutations reduce MMR activity, increasing the likelihood of DNA mutations; and thus, the risk of cancer. Due to reduced MMR function, LS patients have a reduced ability to manage DNA damage caused by OS and inflammation; therefore, maintaining OS at a manageable level may reduce the risk of cancer in LS patients.

Nrf2 is a master regulator of the endogenous antioxidant system and nutritional activators of this pathway have been shown to reduce the risk of cancer in the general population through modulation of OS. Since LS patients are more susceptible to cancer caused by OS, nutritional Nrf2 activators have the potential to reduce the risk of cancer in those with LS by modulating OS and inflammation.